戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                          The antichlamydial activities of two of these INPs, INPs 034
2 nsive search of the chemical space for novel antichlamydial activities, we identified over 60 compoun
3 ere chlamydicidal and induced MdM to express antichlamydial activity and (ii) although polymorphonucl
4                                Finally, both antichlamydial activity and cytotoxicity of the lead com
5  the present study 25 INPs were screened for antichlamydial activity at a concentration of 50 muM, an
6                         Despite their potent antichlamydial activity in vitro, neither heparin nor de
7 oniae is a target organism, antibiotics with antichlamydial activity may be able to ameliorate plaque
8  that C. trachomatis Pgp3 can neutralize the antichlamydial activity of human cathelicidin LL-37, a h
9                                          The antichlamydial activity of INP0341 was retained when tes
10                    In conclusion, the potent antichlamydial activity of INPs is directly or indirectl
11                                              Antichlamydial activity resided principally in residues
12 ydrothiazepine library and characterized its antichlamydial activity using a modified semi-high-throu
13 cation of LpxC inhibitors as unique class of antichlamydial agents.
14 onditioned medium from these macrophages was antichlamydial and contained elevated levels of interleu
15      There was no staining with any of the 3 antichlamydial antibodies in formalin-fixed brain tissue
16                                    In vitro, antichlamydial antibodies increased the rate of Th1 acti
17 in-fixed brain tissue, by use of 3 different antichlamydial antibodies.
18 delayed-type hypersensitivity responses, but antichlamydial antibody responses were unaffected.
19 n improving the developability profile of an antichlamydial chemical class previously reported by our
20         Critically, we found the most potent antichlamydial compound to inhibit fatty acid biosynthes
21 rting point for the development of selective antichlamydial drugs.
22 int for the development of new and selective antichlamydial drugs.
23 acylhydrazides with the goal to uncouple the antichlamydial effect from iron starvation.
24 ydial infection, which may contribute to the antichlamydial effect of IL-17.
25                However, the role of NO as an antichlamydial effector could not be clearly demonstrate
26  chelate iron, and it is possible that their antichlamydial effects are caused by iron starvation.
27 response, including elevated titers of serum antichlamydial IgG2a and IgG2b, not IgG1, and elevated l
28  that infection fails to elicit a protective antichlamydial immune response.
29 esence did not correlate with evidence of an antichlamydial immune response.
30 pes, leading to the generation of protective antichlamydial immunity and making these mice a valuable
31 r mononuclear infiltrates, primarily mediate antichlamydial immunity.
32                        Because of the potent antichlamydial immunizing properties of DC, we hypothesi
33 rt tool in the identification of more potent antichlamydial molecules.
34 is one of the main challenges of the current antichlamydial pharmacotherapy.
35  as holo-transferrin, was able to negate the antichlamydial properties of the INPs.
36            Longer-term and larger studies of antichlamydial therapy are indicated.
37 ng the foundation for an additional specific antichlamydial therapy by small molecules.
38  a small molecule lead compound for specific antichlamydial therapy, which showed drastically lowered
39 ng subjects who may potentially benefit from antichlamydial therapy.
40  has proven to be a promising new target for antichlamydial therapy.
41                 Despite considerable effort, antichlamydial vaccines have proven to be elusive using